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CLINICAL PRACTICE
New considerations about Chiari-
like malformation, syringomyelia 
and their management
Background: Chiari-like malformation (CM) is a developmental condition, characterised by a 
conformational change and overcrowding of the brain and cranial cervical spinal cord. CM-associated 
pain (CM-P) and syringomyelia are increasingly being diagnosed, due to the rising popularity of 
predisposed brachycephalic breeds and the availability of MRI in veterinary practices. 
Aim of the article: This article aims to update the veterinary profession on these conditions, and 
provides a guide to diagnosis and treatment of clinically relevant disease.
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KEY LEARNING OUTCOMES
After reading this article, you should understand:
 ▢ Clinical signs of Chiari-like malformation-associated pain and 
differential diagnosis;
 ▢ Clinical signs of syringomyelia and differential diagnosis; 
 ▢ Diagnosis and MRI appearance of Chiari-like malformation-
associated pain and syringomyelia; 
 ▢ Medical and surgical management options for Chiari-like 
malformation-associated pain and syringomyelia; 
 ▢ Breeding recommendations for dog breeds and crossbreeds 
predisposed to Chiari-like malformation-associated pain and 
syringomyelia.
doi: 10.1136/inp.m1869
Introduction
Chiari-like malformation (CM) is a complex 
developmental condition of the skull and 
craniocervical vertebrae, and is characterised by 
a conformational change and overcrowding of 
the brain and cervical spinal cord, particularly 
at the craniospinal junction. Obstruction to 
cerebrospinal fluid (CSF) channels can result in 
pain and a tendency for fluid cavitation of the spinal 
cord, called syringomyelia (SM) (Figs 1 to 3). The 
fluid within the cavities (singular syrinx, plural 
syringes) is similar to CSF. These fluid pockets can 
expand and can cause irreversible damage to the 
spinal cord, resulting in clinical signs of pain and 
neurological deficits. 
The rising popularity of predisposed 
brachycephalic toy breed dogs and availability of 
MRI has seen CM-associated pain (CM-P) and SM 
becoming a more common diagnosis in veterinary 
medicine. CM-P can be a challenging diagnosis 
because the signs of pain are non-specific and, 
unlike SM, MRI diagnosis of CM-P is poorly defined 
or ambiguous. A degree of CM is ubiquitous in 
predisposed breeds and CM-P can be late onset, 
meaning it is challenging to distinguish clinically 
affected dogs using MRI (Figs 1, 2). 
Nomenclature
The eponymous term Chiari malformation refers 
to the first detailed description of the analogous 
human condition by Hans Chiari in 1891 and 
classically describes a cerebellar herniation 
through the foramen magnum. Alternative names 
for the canine condition include caudal occipital 
malformation syndrome (COMS) and occipital 
hypoplasia. None of these names are ideal because 
the malformation is more complex than a cerebellar 
herniation, simple occipital bone abnormality or 
small volume caudal fossa. 
An alternative term, brachycephalic obstructive 
cerebrospinal fluid channel syndrome (BOCCS), was 
proposed to reflect the connection to brachycephaly 
and obstruction of CSF pathways. However, as 
CM was the terminology decided at a round table 
discussion (Capello and Rusbridge 2007), this is the 
most commonly accepted moniker. 
The nomenclature of SM has morphed over 
the years since the first description in the early 
19th century. Authoritative sources use SM 
rather than historical terms syringohydromyelia, 
hydrosyringomyelia or hydromyelia. This is because 
the anatomical distinction between these terms 
is theoretical rather than a reality (Rusbridge 
and Flint 2014). It is conventional in veterinary 
medicine to refer to a central syrinx, less than 2 mm 
in transverse diameter, as a central canal dilation 
(Fig 3), even though the ependymal lining of the 
central canal is disrupted with only minor dilation 
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(Radojicic and others 2007). Non-inflammatory 
spinal cord oedema, as distinct from cavities 
containing free fluid, is referred to as presyrinx 
(presyringomyelia). Presyrinx most commonly 
affects the dorsal and ventral columns of the spinal 
cord and may eventually progress to SM (Fig 3). The 
oedema can reverse if the cause can be addressed. 
CNS inflammatory diseases can also cause spinal 
cord oedema and are alternative differentials for 
spinal cord oedema (Fig 4). 
Signalment and prevalence 
Brachycephaly with airorhynchy (ie, retroflexion of 
the facial skeleton on the cranial base) is the major 
risk factor for CM-P and SM. Any animal with skull 
shortening including the muzzle with, in dogs, 
concurrent whole body miniaturisation could be 
predisposed. The condition is most common in 
Cavalier King Charles spaniels (CKCS) and their 
crosses (eg, cavapoos), especially if the cross is with 
a smaller dog than a CKCS. Other breeds with high 
Fig 1: Spectrum of Chiari-like malformation (CM) and syringomyelia (SM) in Cavalier King Charles spaniels (CKCS), ranging from clinically unaffected to affected . 
T2W midsagittal MRI of the head and cranial cervical region. (a) Normal CKCS (CM-N). Three-year-old male, neutered, 17 kg dog that presented with lumbar pain 
due to L3/L4 intervertebral disc (IVD) extrusion. (b) Normal CKCS (CM-N). Seven-year-old male, entire, 16 kg dog illustrates the grey area between normal and 
abnormal. This dog presented with acute-onset cervical pain related to a C3/C4 IVD extrusion. There was no previous history consistent with  
CM-associated pain (CM-P) and the cervical pain resolved after surgical decompression of the IVD extrusion. The appearance of the skull, craniocervical 
junction and brain is only subtly different from the clinically affected dogs and there is a cerebellar herniation. (c) CKCS with CM-P. Seven-year-old female, 
neutered, 11 kg dog was presented because of repeated vocalisation as if it was in pain when falling asleep, together with unwillingness to rise, an aversion to 
its ears being touched, walking slowly upstairs, and yelping when being picked up from under the sternum. (d) CKCS with SM-specific signs (SM-S).  
Seven-year-old female, neutered, 7.3 kg dog that presented with a scratching action towards the shoulder area without making skin contact and when walking 
on a lead, mostly with the right pelvic limb but sometimes with the left. Red line – outline of the muzzle, stop and ‘forehead’. The angle of stop and the size of 
frontal sinus progressively reduces with clinical affectedness. Yellow line – progressive rostral flattening of the forebrain with clinical affectedness.  
Green shading – progressive reduction and ventral displacement of the olfactory bulbs with clinical affectedness. Purple shading – progressive shortening 
and reduction of the basicranium, especially the presphenoid bone with clinical affectedness. Turquoise arrows – in CM-P and SM-S the forebrain is displaced 
caudally. The space for the hindbrain is compromised rostrally by the forebrain and caudally by the small caudal skull. The cerebellum loses its rounded shape 
and is pushed out of the foramen magnum. Blue line – with increasing clinical affectedness, the supraoccipital bone becomes flatter and shorter and the 
opisthion (dorsal foramen magnum) becomes rostral with respect to the occipital crest. Orange star – progressive reduction in bony tissue of the occipital crest 
as the dog becomes more clinically affected; however, sexual dimorphism may also influence this
Fig 2: Spectrum of changes of Chiari-like malformation (CM) 
and syringomyelia (SM), ranging from clinically unaffected to 
affected Cavalier King Charles spaniels (CKCS). T2W MRI of 
the midsagittal head and cranial cervical region.  
(a) Normal CKCS (CM-N). (b) Normal CKCS (CM-N), illustrating  
the grey area between normal and abnormal. (c) CKCS with 
CM-associated pain (CM-P). (d) CKCS with SM-specific signs 
(SM-S). The signalment and descriptions of dogs are the 
same as for Fig 1.
Pink shading – from (a) to (d), the rough outline of the 
forebrain changes from a rugby to a football shape because 
of increasing brachycephaly. White line – progressive ventral 
rotation of the axis of the brain. Yellow star – SM. Turquoise 
line – change in the conformation of the craniospinal 
junction because of craniovertebral junction (occiput, atlas, 
and axis) malformation. The atlas is closer to the skull with 
cervical flexure and acute angulation of the odontoid peg, 
resulting in kinking or elevation of the neuroparenchyma
(a) (c) (d)(b)
(a) (b)
(c) (d)
CM-N CM-P SM-SCM-N
CM-N CM-N
CM-P SM-S
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prevalence include King Charles spaniels, griffon 
bruxellois, affenpinschers, Chihuahuas, Yorkshire 
terriers, maltese, Pomeranians and brachycephalic 
cats, especially Persians. Occasionally affected dog 
breeds include French bulldogs, Boston terriers, 
pugs, havanese, miniature dachshunds, miniature/
toy poodles, bichon frisé, and miniature pinschers. 
Surprisingly, many toy breeds with extreme facial 
foreshortening such as the Pekinese, Japanese chin 
and shi tzu, are not as predisposed, perhaps reflecting 
a different skull shape, brain size and genetic heritage.
When MRI is performed in predisposed breeds, CM 
is commonly reported, and SM may be an incidental 
finding. Care must be taken to not overdiagnose, 
and MRI results should be related to historical and 
clinical findings. Cerda-Gonzalez and others (2009) 
found that 92 per cent of CKCS had at least one 
craniocervical morphological abnormality detected 
on MRI, and studies looking at groups of 16 or more 
clinically unaffected CKCS found a high incidence of 
SM, ranging from 26.5 per cent (Cerda-Gonzalez and 
others 2009) to 65.4 per cent (Rusbridge and others 
2007). These figures increased to 42 per cent and 74.5 
per cent, respectively, when dogs with clinical signs 
were added to the population. 
Dogs may be presented with the disease at any 
age, although many dogs (approximately 45 per cent) 
will develop first signs of the disease within the first 
year of life, and approximately 40 per cent of cases 
have first signs between one and four years of age. 
As many as 15 per cent develop signs as mature dogs 
(aged between six and eight years of age) (Plessas 
and others 2012, Thofner and others 2015). 
Pathophysiology 
Chiari-like malformation 
CM is a developmental malformation characterised 
by neuroparenchymal disproportion – the ‘box’ 
(skull and cranial cervical vertebrae) is too ‘short’ 
for the contents (brain and cranial cervical spinal 
cord). The key feature of canine CM is premature 
suture closure (craniosynostosis) and insufficiency 
of bones forming the skull base and caudal skull 
(Figs 1, 2). CM is also characterised by a reduction 
in craniofacial tissue with a loss of the frontal 
sinus and a more defined ‘stop’ (Knowler and 
others 2020). The ‘stop’ is the pronounced angle 
between the nasal/maxilla bones and the frontal 
bones, which is a defining feature of domesticated 
mesaticephalic and brachycephalic dogs and 
by contrast is not present in wolves. The skull 
Fig 3: T2W midsagittal cervical MRI (left) and T2W transverse MRI at level of C2/C3 (right), showing the spectrum of changes from normal to syringomyelia (SM).  
(a) Normal MRI appearance in a dog. (b) Central canal dilatation (blue arrow). (c) Area of presyrinx (green arrow) in the spinal cord (dorsal) and ventral columns 
surrounding a small syrinx. (d) The same dog as in (c) but six years later and now with a fully developed SM (red arrows) which is asymmetrical and expanding 
the spinal cord
Fig 4: MRI images from a three-year-old male, neutered Cavalier King Charles spaniel (CKCS) 
presenting with cervical pain and reluctance to walk. (a) T2W midsagittal MRI of neuroaxis 
from hindbrain to T8. (b) Transverse T2W MRI at level of C2. (c) Parasagittal T2W MRI at the 
level of the mesial temporal lobe. (d) Transverse T2 MRI at the level of the mesial temporal 
lobe and thalamus. (e) Transverse fluid-attenuated inversion recovery (FLAIR) MRI at the 
level of the mesial temporal lobe and thalamus. (f ) Transverse T1W MRI with paramagnetic 
contrast at level of C2. (g) Midsagittal T1W MRI with paramagnetic contrast of neuroaxis 
between hindbrain and C3. Hyperintensity on T2W images suggest spinal cord oedema 
(turquoise arrow), but unlike the case in Fig 3 the oedema is within in the grey matter rather 
than the dorsal columns. The white matter of the dorsal column is hypointense on T2W 
(red star) and enhances with paramagnetic contrast (red arrows). These images support 
suspicion of multifocal inflammatory or neoplastic disease with hyperintensity in the 
region of the mesial temporal (green arrows) and periventricular and meningeal tissue – 
meningoencephalomyelitis is an important differential for spinal cord oedema. CSF analysis 
revealed a mononuclear (lymphocyte dominant) pleocytosis with a white blood cell count 
of 1386 cells/ul and a protein concentration of 614.8 mg/dl. PCR for antigen receptor gene 
rearrangements clonality did not support lymphoma. Testing for common infectious diseases 
was negative
(a)
(c)
(b)
(d)
(a)
(b)
(c)
(d) (e) (f) (g)
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insufficiency results in rostrotentorial (forebrain) 
crowding which further reduces the functional 
caudotentorial space and causes hindbrain 
herniation. In addition, some predisposed breeds, 
such as CKCS, have comparatively big brains. 
Chiari malformation-associated pain
CM-P is defined as the clinical signs of pain 
relating to CM. Compared to clinically normal 
dogs with CM (CM-N), dogs with CM-P have more 
extreme brachycephaly; that is, shorter cranial 
base, more craniofacial hypoplasia with greater 
neuroparenchymal disproportion and overcrowding 
(Knowler and others 2017) (Figs 1, 2). 
Syringomyelia 
There is yet to be an entirely satisfactory explanation 
of how fluid cavities develop in the spinal cord 
following CSF pathway obstruction. Whether syrinx 
fluid is derived from extracellular fluid or CSF is 
Table 1: Clinical signs of Chiari-like malformation-associated pain 
Clinical signs Frequency 
(% affected 
dogs)
Notes 
Vocalisation 65 Yelping described by the owner as ‘out of nowhere’, spontaneous or when the dog is 
moving, while lying resting or asleep, when lifted under the sternum, or on rising
Spinal pain 55 Hyperaesthetic to palpation in the cervical, thoracolumbar or caudal lumbar / lumbosacral 
region
Activity change 38 Described as exercise intolerant, unwilling to exercise, lethargic or sleeping more
Refusal/hesitation/difficulty climbing 
stairs or jumping
35 Described as refusing/hesitating/difficulty or vocalisation when jumping or climbing stairs
Scratching or rubbing of the head or ears 28 Skin and ear disease should be excluded
Aversion to the ears/head/neck being 
touched or groomed
25 Owner reports that the dog has an aversion to touch of this body part, yet tolerates touch or 
grooming elsewhere
Sleep disruption 22 Described as being restless in the night or having disturbed sleep
Timid/anxious 14 Change in behaviour described by owner
Withdrawn 13 Change in demeanour described by owner
Forelimb hypermetria 10 ‘Goose stepping’-type gait characterised by increased proximal joint movement giving a 
tendency to overshoot. May also have decreased distal joint movement due to increased 
muscle tone (due to cerebellar dysfunction or a spinocerebellar tract lesion)
Aggression 8 Change in behaviour or uncharacteristic belligerence to other dogs/people
Abnormal head/neck posture when 
awake
8 Head held down or reluctant to move neck
Vocalisation when greeting, refusal to 
rise to greet, or no longer greeting
5 Yelping during greeting or refusal to get up and greet owner
Sleeping with an elevated or unusual 
head posture
5 Brachycephalic obstructive airway syndrome could be an alternate explanation for this sign
Aversion to the sternum or flank being 
touched or groomed
5 Owner reports that the dog has an aversion to touch of this body part, yet tolerates touch or 
grooming elsewhere
Squinting/avoiding light 5 Described by the owner as avoiding looking at lights or closing eye in light. Schirmer tear 
test should be performed to eliminate a diagnosis of keratoconjunctivitis sicca
Vocalisation when scratching 5 Yelping while scratching
Licking limb/paw 4 Dog licks without evidence of skin or orthopaedic disease and does not respond to trial 
management for allergic skin disease
Pain face 3 Owner describes a grimacing facial expression, suggesting the dog is in pain
Aversion to the limb/paw being touched 
or groomed
3 Owner reports that the dog has an aversion to touch of this body part, yet tolerates touch or 
grooming elsewhere
Vocalisation when defecating 2 Yelping while defecating
Repetitive barking 2 Behaviour thought to reflect anxiety; not necessarily due to Chiari-like malformation-
associated pain (CM-P)
Frequency is based on owner-reported and clinical examination findings in CM-P and syringomyelia affected Cavalier King Charles spaniels (Rusbridge and others 2019) 
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also controversial. The most accepted theory of the 
pathogenesis of SM is that obstruction to CSF flow 
in the subarachnoid space results in a mismatch 
in timing between the spinal arterial pulse peak 
pressure and CSF pulse peak pressure. Earlier arrival 
of peak CSF pressure encourages flow of CSF into the 
perivascular space. The perivascular space changes 
in size during the cardiac cycle and is widest when 
spinal arteriole pressure is low. If at that time peak 
CSF pressure is high, then the perivascular space 
could act as a ‘leaky’ one-way valve. From the 
perivascular space, fluid flows into the central canal 
ultimately resulting in a syrinx (Stoodley 2014).
SM can occur due to any obstruction to CSF 
pathways and has been reported in a variety of 
disorders, including acquired cerebellar herniation 
secondary to intracranial masses, spinal arachnoid 
diverticulum, spinal cord tethering and inflammatory 
conditions, such as feline infectious peritonitis. 
However, in canine medicine by far the most common 
cause is CM. The pathogenesis of SM associated with 
CM is predisposed by two morphological phenotypes: 
more extreme brachycephaly, as for CM-P, and 
craniocervical junction deformation, including 
changes in angulation of the dens and increased 
proximity of the atlas to the skull and loss of the 
cisterna magna (Figs 1, 2). Loss of the cisterna magna 
or other alterations in the CSF volume will affect the 
compliance of the CNS. This may be influenced by 
poor venous drainage, intracranial hypertension, and 
conformational features of the spinal canal. 
Clinical signs
Chiari-like malformation
CM-P is thought to relate to a failure to equilibrate 
intracranial pressure due to obstruction of CSF 
pathways. Intracranial pressure is affected by 
the systolic pulse, venous drainage, the balance 
between CSF production and absorption and 
microgravitational effects (eg, when being lifted 
rapidly or when the head position moves rapidly). 
In people, pain in CM is exacerbated by the Valsalva 
manoeuvre, a brief increase in intrathoracic pressure, 
for example when coughing or with abdominal 
straining. Signs of canine CM-P (Table 1) include:
■■ Vocalisation (described as without obvious trigger, 
when shifting position when recumbent and when 
being lifted under the sternum to a height);
■■  Spinal pain; 
■■ Head and ear rubbing or scratching; 
■■ Aversion to touch; 
■■ Refusal or difficulty jumping or climbing stairs;
■■ Exercise intolerance/reduced activity; 
■■ Sleep disruption; 
■■ Behavioural change described as becoming more 
anxious, timid, aggressive or withdrawn. 
Syringomyelia
SM-specific signs (SM-S) are associated with large 
syringes (in CKCS a maximum transverse width of 
equal to or greater than 4 mm) and include phantom 
scratching, scoliosis and sensory and motor signs. 
The neurolocalisation is consistent with the syrinx 
location (Table 2). 
The signs of CM-P and SM (except phantom 
scratching) are non-specific. Therefore, other 
possible explanations should be eliminated. 
Neurological deficits associated with SM will have 
the same neurolocalisation as the syringe; however, 
gait disturbances and paresis may be surprisingly 
mild even with wide SM involving the entire cervical 
to lumbar spinal cord. Typically, the thoracic limbs 
are weaker than the pelvic limbs, reflecting the 
central spinal cord damage. Other differentials 
Table 2: Clinical signs of clinically relevant syringomyelia*
Clinical signs Frequency (% 
affected with 
CM-P and SM)
Frequency (% 
affected with 
SM-S)
Notes 
Phantom scratching 43 67 Rhythmic scratching action towards neck, but not contacting the skin, together with a 
curvature of the body and neck towards the foot. Induced by light rubbing of the neck 
or ear region and triggered by excitement, anxiety and exercise. Associated with a large 
mid-cervical syringe extending to the superficial dorsal horn ipsilateral to the scratching
Scoliosis/
cervicothoracic 
torticollis 
18 27 Corkscrew deviation of neck associated with a large mid-cervical syringe extending to 
the superficial dorsal horn ipsilateral to lateral shoulder deviation and contralateral to 
the ventral head tilt
Weakness 25 39 Thoracic limb and paraspinal muscle weakness associated with a large cervicothoracic 
syringe
Thoracic limb muscle 
atrophy 
4 6 Thoracic limb muscle atrophy associated with a large C5-T1 spinal segment syringe
Postural responses 
decreased
10 15 As demonstrated by ‘hopping’, ‘hemi-walking’ and ‘correction of knuckled over paw’ 
testing. Thoracic limbs are typically more affected than pelvic limbs. Consider other 
differentials if the dog presents with severe paraparesis
CM-P Chiari-like malformation-associated pain, SM-S Syringomyelia-specific signs
Frequency is based on owner-reported and clinical examination findings in CM-P and SM affected Cavalier King Charles spaniels (Rusbridge and others 2019) 
* That is, SM-S (maximum transverse width equal to or greater than 4 mm ) 
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Table 3: Common differential diagnosis for CM-P and SM and unrelated comorbidities common in CKCS 
Condition Clinical signs Notes 
Other neurological signs
Idiopathic epilepsy Seizures, normal interictal neurological examination No link between CM/SM and epilepsy has been proved. 
Considered separate diseases for management 
purposes
Paroxysmal dyskinesia 
(epileptoid cramping 
syndrome/Spike’s disease) 
Episodes of abnormal movement that are self-limiting 
with long periods of normality between episodes. 
Abnormal movements may include tremor, alternate limb 
lifting/flexion and weaving head movements with variable 
gastrointestinal signs. Animal remains conscious and 
able to respond to owner (eg, may try to walk to owner)
Possible connection to gastrointestinal dysfunction 
and gluten sensitivity. Episodes may reduce with a 
hypoallergenic or gluten free diet
Fly catching disorder Behaviour where the dog acts as if watching/catching a 
fly (although ignores actual flies). Some may also behave 
as if their ears or feet are irritated and some can also tail 
chase. May be more likely with certain light intensities and 
emotional states
Possible connection to gastrointestinal dysfunction. 
Episodes may reduce with a hypoallergenic or low protein 
diet. Neurochemical imbalance has been suggested as 
some dogs respond to anti-epilepsy drugs or selective 
serotonin re-uptake inhibitors
Myoclonus Brief jerking of the head, often with buckling of a thoracic 
limb when the dog is standing or sitting
Older CKCS (over five years old). Initially relatively benign 
but can be progressive over years and the myoclonic 
jerks can cause the dog to fall or stumble
Episodic falling (paroxysmal 
exercise-induced dyskinesia)
Falling episodes induced by physical activity, stress 
and excitement, and manifest with hypertonicity of the 
limbs resulting in inability to move or even complete 
collapse. In contrast to epileptic seizures, consciousness 
is unaffected
Movement disorder associated with BCAN (brevican) 
mutation. Typically manifests between the age of four 
months and four years. A genetic test is available
Idiopathic facial paresis Inability to close the eye or move the lips, ears or other 
facial muscles. Facial sensation (trigeminal nerve) is 
normal
May be bilateral (not necessarily simultaneously) in 
CKCS, or associated with vestibular signs
Other causes of head tilt
Idiopathic vestibular disease Acute onset vestibular signs (head tilt, nystagmus, 
positional strabismus, asymmetrical ataxia) with no 
proprioceptive deficits or weakness
In CKCS idiopathic vestibular disease has two variations: 
one in geriatric dogs and one in middle-aged dogs often 
in conjunction with idiopathic facial paresis
Rostral cerebellar artery 
infarction
Acute-onset paradoxical vestibular signs with other 
signs suggesting a cerebellar location (menace response 
deficit, intention tremor, decerebellate posture)
Often improves with supportive care
Other causes of spinal pain or myelopathy (proprioceptive deficits and paresis)
Atlantoaxial subluxation Myelopathy localising to the cranial cervical spinal cord 
(tetraparesis, increased muscle tone, proprioceptive 
deficits and possible respiratory compromise)
May be seen in association with CM-P and SM, especially 
in miniature breeds such as Chihuahuas and Yorkshire 
terriers
IVDD – cervical Neck pain and variable limb postural deficits. May be 
associated with neck muscle myoclonus (C3 nerve root 
compression/irritation) or lameness (C5-C8 nerve root 
compression/irritation)
In contrast to CM/SM, IVDD typically occurs in older dogs 
(two years of age or older) and spinal pain is typically 
acute onset and focal
IVDD – thoracolumbar Acute-onset focal pain in T11-L4 region with variable 
myelopathy (paraparesis and proprioceptive deficits)
IVDD – lumbosacral Refusal/hesitation/difficulty in jumping or climbing the 
stairs. Focal pain in lumbosacral region. Unilateral or 
bilateral pelvic limb lameness. Hyperaesthesia in the 
distribution of the L7 nerve root
Meningoencephalomyelitis of 
unknown origin 
Spinal pain with variable neurological signs relating to 
immune-mediated inflammation of the brain or spinal 
cord
Inflammatory disease will also result in a high 
intrathecal signal on T2 weighted images (see Fig 4)
Degenerative myelopathy 
associated with gain of 
function SOD-1 mutation
Pelvic limb proprioceptive deficits and paraparesis (T3-
L3 localisation), progressing over months to paraplegia 
with faecal and urinary incontinence, and over years to 
tetraplegia. Non-painful
Even with wide SM, significant pelvic limb weakness and 
proprioceptive deficits is unusual and other differentials 
should be considered. A genetic test for the SOD-1 
mutation is available
CKCS Cavalier King Charles spaniel, CM-P Chiari-like malformation-associated pain, IVDD Intervertebral disc disease, SM Syringomyelia, SOD1 Superoxide dismutase 1
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should be considered if there is a non-ambulatory 
tetraparesis or severe paraparesis (Table 3). 
Likewise, SM is a spinal cord disease and so would 
not result in epilepsy, facial nerve paralysis or fly 
catching disorder. CKCS are predisposed to several 
neurological conditions and comorbidities (Table 3). 
Diagnosis 
Chiari-like malformation 
CM-P is a diagnosis of exclusion in a predisposed 
breed or in a dog presenting with the signs mentioned 
earlier. MRI remains the only diagnostic test to support 
suspicion of CM-P. Although the bony changes can 
be demonstrated by CT, MRI is required to detect any 
associated SM. When undertaking brain and cervical 
MRI of a predisposed breed, it is recommended that 
the dog’s microchip or tattoo number (confirmed by 
the vet) is included on the DICOM (digital imaging 
and communications in medicine) images in addition 
to the Kennel Club registration number, if relevant, 
even if CM-P or SM is not a differential. This is to 
permit submission to the BVA/Kennel Club’s Chiari 
malformation/syringomyelia (CM/SM) scheme should 
the owner request this following the imaging (BVA 
2013). For details of MRI protocols to investigate CM 
and SM see Rusbridge and others (2018). 
MRI changes (Box 1) (Figs 1, 2) can support 
but not confirm the diagnosis of CM-P. Research 
techniques such as MRI-based morphological 
measurements or machine learning have yet to be 
adapted to the clinic (Spiteri and others 2019). 
Syringomyelia 
MRI is required for diagnosis of SM (Box 2). The 
finding of SM implies a fluid-filled cavity related to 
disturbance of CSF flow, spinal cord tethering or 
intramedullary tumour. The cause of SM should be 
determined (Rusbridge and others 2018). SM is not 
an appropriate description for myelomalacia or cystic 
lesions. SM can be an incidental finding, and when 
interpreting MRI an assessment should be made as 
to whether the location and severity of the syrinx 
would account for the signs. It would be exceptional 
for SM associated with CM to result in a myelopathy 
localising to T3-L3 with pelvic limb paresis and 
proprioceptive deficits and normal thoracic limb 
function. If this is the neurological localisation then 
other differentials should be investigated (Table 3). 
Progression and prognosis 
There is paucity of large studies on the progression 
and long-term outcome of dogs affected by CM-P 
and SM. Studies in breeding CKCS suggest that the 
proportion of affected CKCS increase from 25 per cent 
at one year of age to 60 per cent at three years of age. 
By five years of age, 70 per cent of the population 
have MRI evidence of SM (Parker and others 2011). 
Although syrinx width increases over time, the 
rate of increase is not constant and it is my unproven 
impression, supported by computer modelling, 
that for many dogs the syrinx develops relatively 
rapidly but then remains remarkably unchanged 
over years having achieved a dynamic equilibrium. 
Table 3 continued: Common differential diagnosis for CM-P and SM and unrelated comorbidities common in CKCS
Condition Clinical signs Notes 
Other causes of head and ear rubbing or scratching
Otitis media with effusion 
(OME; also known as primary 
secretary otitis media)
Sequel of brachycephalic conformation and poor drainage 
of the middle ear. May cause hearing loss or ear discomfort
OME is a possible differential for ear pain or rubbing 
(Guerin and others 2015); however, Rusbridge and 
others (2019) did not find OME presence significantly 
associated with head/ear rubbing or scratching
Allergic skin disease Generalised pruritus, especially of the feet and abdomen CM-P and SM are not associated with pruritus of the 
ventral abdomen, feet or tail head
Periodontal disease Oral pain with inflammation of the gingiva and 
deterioration of the bone and soft tissue structures 
supporting the teeth
Higher prevalence in small breeds and significant 
association with cardiac disease (Pereira dos Santos 
and others 2019)
Other causes of sleep disruption, exercise intolerance or lethargy
Brachycephalic obstructive 
airway disease
Exercise, heat intolerance, sleep disordered breathing or 
sleep apnoea
Important differential for sleep disruption. Consider if 
the dog is waking up spluttering or coughing
Degenerative mitral valve 
disease
Left apical systolic murmur, exercise intolerance, coughing, 
respiratory effort, nocturnal dyspnoea, pulmonary oedema
Important differential for exercise intolerance
Chronic pancreatitis Recurrent anorexia, mild bouts of colitis-like faeces, 
occasional vomiting, increased borborygmi, mild 
abdominal pain
Differential for signs of lethargy and behavioural 
changes suggesting pain
Gastro-oesophageal reflux 
disease
Classic signs like regurgitation not always present/obvious. 
Discomfort or pain may manifest as repetitive tongue 
licking or restlessness
Differential for behavioural changes suggesting pain
CKCS Cavalier King Charles spaniel, CM-P Chiari-like malformation-associated pain, SM Syringomyelia
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Clinical signs will progress in approximately 75 per 
cent of dogs and approximately 15 per cent will be 
euthanased because of CM-P and SM-S. 
However, despite progressive signs, many dogs 
with signs of pain and phantom scratching respond 
to medical management and are considered by their 
owners to have an acceptable quality of life (Plessas 
and others 2012). Cervicotorticollis may slowly improve 
despite persistence of the syrinx. Dogs that are 
presented with SM-S before three years of age seem to 
have a poorer prognosis and are more likely to develop 
severe weakness which is more difficult to treat.
 
Medical management 
Medical management of SM is based mostly on 
anecdotal reports and typically relies on adjuvant 
analgesics and other unlicensed medication (Fig 5) 
(Table 4). There have been three short-term (14 to 25 
day) clinical trials assessing carprofen, gabapentin 
and topiramate (Plessas and others 2015) and 
pregabalin (Sanchis-Mora and others 2019, Thoefner 
and others 2020), in addition to one long-term (39 
[±14.3] months) outcome study (Plessas and others 
2012). For the short-term studies, quality of life was 
improved following prescription of topiramate and 
gabapentin, but not after prescription of carprofen 
alone (Plessas and others 2015). Prescription of 
pregabalin improved owner-reported pain scores, 
mechanical hyperalgesia, cold hyperalgesia, cold 
allodynia and was efficacious for treatment of 
neuropathic pain (Sanchis-Mora and others 2019) and 
SM-associated phantom scratching (Thoefner and 
others 2020). For the long-term outcome study, 75 per 
cent of medically managed dogs had an acceptable 
quality of life at the end of the follow-up period; the 
most common medication prescribed was gabapentin 
or pregabalin (Plessas and others 2012). From this, one 
can conclude there is poor evidence that clinical signs 
of pain will improve with prescription of carprofen 
alone, there is some evidence of improvement 
with combination of carprofen and gabapentin or 
carprofen and topiramate, and reasonable evidence of 
improvement with pregabalin. 
Anecdotally, a positive response to antacids, 
such as cimetidine or omeprazole, is reported. The 
principle is that these drugs reduce CSF production 
thus reducing the driving force contributing to CM-P 
and SM. However, studies assessing the effect of 
omeprazole on CSF production by evaluating the 
albumen quotient (QAlb; ratio between CSF and 
serum albumin concentration) did not support 
a CSF-reducing effect (Girod and others 2016), 
although the validity of QAlb as a surrogate marker 
for CSF production was later disputed (Girod and 
others 2019). More importantly, omeprazole may not 
achieve a therapeutic choroid plexus concentration, 
BOX 1: MRI FEATURES OF CHIARI-LIKE MALFORMATION-ASSOCIATED PAIN 
■■ Craniofacial hypoplasia with absent or minuscule frontal sinuses and reduction in maxillary height. 
Junction between nasal and maxilla forming an angle rather than a slope. 
• Simple explanation: facial features of a ‘forehead’ formed by the frontal bone overlying the brain with 
no or minuscule frontal sinus, together with well-defined or indented stop and a muzzle which is short 
in height and length (see Fig 1).
■■ Rostrotentorial overcrowding resulting in rostral flattening of the forebrain, reduction and ventral 
displacement of the olfactory bulbs and increased height of the cranium, especially in the occipital 
region (see Fig 1). 
• Simple explanation: the forebrain changes from a rugby to a football shape (see Fig 2). The olfactory 
bulbs are small and are directed ventrally rather than rostrally. 
■■ Obstruction of cerebrospinal fluid (CSF) channels: reduction in the cranial and spinal subarachnoid 
space in addition to ventriculomegaly of all ventricles and cisterns, except the cisterna magna which is 
often reduced.
• Simple explanation: on T2-weighted (T2W) imaging there is less ‘white’ hyperintense fluid signal in the 
CSF space around the brain and spinal cord. By contrast, the CSF spaces within the brain are enlarged.
■■ Shortening of the basicranium especially the presphenoid bone. 
• Simple explanation: a short skull base. 
■■ Small caudal cranial fossa, the supraoccipital bone is flatter and the opisthion (dorsal foramen magnum) 
is rostral with respect to the occipital crest (see Fig 1). 
• Simple explanation: the back of the skull containing the hindbrain is small. 
■■ Rostrotentorial neuroparenchyma is displaced dorsocaudally reducing the functional caudotentorial 
space contributing to a hindbrain herniation.
• Simple explanation: the forebrain is displaced caudally. The space for the hindbrain is compromised 
rostrally by the forebrain and caudally by the small caudal skull. The cerebellum loses its rounded 
shape and is pushed out of the foramen magnum. 
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so the effect, if any, of antacids on CSF production 
remains unsubstantiated. 
Surgical management 
There are three recognised surgical options 
for management of CM-P and SM-S, but none 
are entirely satisfactory. To date, no published 
surgical series has provided MRI evidence of 
sustained collapse of the syringe postoperatively. 
Documenting that syrinx does not increase in size 
is not proof of surgical efficacy. If the postoperative 
MRI reveals a syrinx which is expanding the spinal 
cord outline then there is active filling. Likewise, 
surgical efficacy is not proved by stabilisation 
of clinical signs, as many dogs can be managed 
successfully on medical management. 
BOX 2: MRI FEATURES OF SYRINGOMYELIA-SPECIFIC SIGNS ASSOCIATED WITH CHIARI-LIKE MALFORMATION 
■■ More extreme brachycephaly than seen with 
Chiari-like malformation-associated pain (CM-P)  
(see Box 1).
■■ Change in the conformation of the craniospinal 
junction (transitional zone between the brain 
and the spine) because of craniovertebral 
junction (occiput, atlas and axis) malformation. 
The atlas is closer to the skull with cervical 
flexure and acute angulation of the odontoid 
peg resulting in kinking/elevation of the 
neuroparenchyma (see Fig 2).
• Simple explanation: there is a concertina-like 
flexure of the bones and nervous tissue at the 
junction between the skull and spine because 
of rostrocaudal shortening. 
■■ Syringomyelia (SM) is a central cavitation 
of the spinal cord with fluid that has similar 
characteristics to cerebrospinal fluid (CSF). 
• For assessment of syrinx severity, transverse 
images of the widest part of the syrinx are 
obtained.  
Myelopathic signs in Cavalier King Charles 
spaniels are associated with a syrinx  
transverse width of 4 mm or more (SM-S)  
(Fig a). 
■■ Phantom scratching and cervicotorticollis/
scoliosis are associated with extension of the 
syrinx into the superficial dorsal horn of the 
cervical spinal cord ipsilateral to the phantom 
scratching side and/or contralateral to the head 
tilt. 
• Simple explanation: extension of the syrinx to 
the edges of cervical spinal cord in the two or 
10 o’clock position is associated with phantom 
scratching and scoliosis. Phantom scratching 
occurs on the same side as the syrinx. In  
scoliosis, the head twists down on the  
opposite side to the syrinx (Fig a)
■■ Fluid signal-void sign within the syrinx cavity 
indicates pulsatile or turbulent flow and is a 
sign of an ‘active’ and filling syrinx more likely to 
expand (Fig a). 
• Simple explanation: on T2-weighted imaging 
‘dark’ hypointense regions within the ‘white’ 
hyperintense syringe indicates moving fluid. 
Surging fluid in the syrinx expands the cavity 
■■ Not all syringes are clinically significant. A 
quiescent syrinx is centrally located, elliptical 
on sagittal images and symmetrical, usually 
circular, on transverse images and results in 
little or no change to the outline of the spinal 
cord. 
• An active and filling syrinx is expansive within 
the spinal cord and generally has an  
asymmetrical shape on transverse images.
• Simple explanation: if the spinal cord outline 
is expanded by the syrinx then it is actively 
filling and more likely significant. A central 
located symmetrical ‘hole’ is less likely to be 
significant (Fig a).
Fig a: T2W MRI midsagittal cervical (i, iv) and transverse at the level of C2 (ii, iii) and C3 (v)  
images, showing clinically relevant (top row) and incidental syringomyelia (bottom row).  
(i) Clinically relevant syringe. The spinal cord outline is expanded by the syrinx indicating 
active filling. Hypointensity within the syrinx cavity (green arrow; fluid signal void sign) 
indicates pulsatile or turbulent flow. (ii) Extension of the syrinx to the edges of spinal cord in 
the 10 o’clock position in the region of the superficial dorsal horn. This finding is associated 
with phantom scratching (same side) and scoliosis (head tilt opposite side). (iii) For 
assessment of syrinx severity, transverse images of the widest part of the syrinx are obtained 
(red arrow). Myelopathic signs in Cavalier King Charles spaniels are associated with a 
syrinx transverse width of 4 mm or more (SM-S). (iv) Incidental syringomyelia – a clinically 
irrelevant syrinx results in little or no change to the outline of the spinal cord and is elliptical 
on sagittal images and circular on transverse images. (v) Transverse image of (iv). There is 
a small syrinx with small surrounding presyrinx. This syrinx is unlikely to be associated with 
current signs of myelopathy but may progress over years 
(i) (ii) (iii)
(iv) (v)
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Table 4: Unlicensed drugs used in the medical management of CM-P and SM-S 
Drug Dose * Notes and adverse effects 
Analgesics
NSAIDs As per data sheet Inhibit production of prostaglandins through actions on cyclooxygenase (COX) pathway.
NSAIDs can result in vomiting and diarrhoea; however, an animal that has an adverse reaction to 
one drug will not necessary react to another. Not recommended for animals with kidney disease. 
Small risk that NSAIDs may precipitate heart failure in animals with pre-existing heart disease
Paracetamol 
(acetaminophen)
10 mg/kg PRN up to TID Central analgesic effect mediating descending serotonergic pathways either through 
inhibition of prostaglandin synthesis or through metabolite influencing cannabinoid receptors 
(Anderson 2008). This drug has been found to be useful for ‘break-through’, short-term pain 
management (ie, allowing the owner to ‘top-up’ existing pain relief). Potential for renal, hepatic, 
gastrointestinal, and haematologic (methemoglobinaemia) adverse effects. High doses can cause 
keratoconjunctivitis sicca (dry eye). Use this drug with caution as dogs do not metabolise it as well 
as people. It is highly toxic to cats so do not use in this species
Adjuvant analgesics
Gabapentin 10–20 mg/kg BID/TID First-generation α2δ ligand (inhibits excitatory voltage-dependant calcium channels). Can result 
in mild sedation and poor coordination, especially when therapy is first started. May increase 
appetite and increased calorific intake may result in weight gain. Therapy should not stop suddenly 
(ie, the drug should be withdrawn slowly). Avoid xylitol-containing suspensions
Pregabalin 5–10 mg/kg BID/TID Second-generation α2δ ligand (inhibits excitatory voltage-dependant calcium channel). Can result 
in mild sedation and poor coordination, especially when therapy is first started. May increase 
appetite and increased calorific intake may result in weight gain. Therapy should not stop suddenly 
(ie, the drug should be withdrawn slowly)
Topiramate 10 mg/kg TID Antiepileptic drug with multiple possible mechanisms of action, including carbonic anhydrase 
inhibition. Little information available for this drug. It should be avoided or used with caution in 
patients with hepatic or renal disease. The most common adverse effect is sedation and ataxia, 
which is more likely with polypharmacy. Gastrointestinal adverse effects including inappetence/
anorexia may be seen. Irritability, aggression, chewing of digits and facial rubbing have be 
reported
Amantadine 3–5 mg/kg PO SID N-methyl-d-aspartate (NMDA) antagonist which may reduce nociceptive activation as adjunctive 
therapy (ie, with another drug). Little information available for this drug. The most common 
adverse effect is sedation and ataxia, which is more likely with polypharmacy. Agitation or 
gastrointestinal adverse effects may be seen. It should be avoided or used with caution in patients 
with glaucoma, hepatic disease, renal disease, congestive heart failure, atopic dermatitis or 
seizure disorders
Memantine 0.3–1 mg/kg BID NMDA antagonist which may reduce nociceptive activation as adjunctive therapy. Very little 
information for this drug; its use in dogs has been described in compulsive disorder, but not 
pain (Schneider and others 2009). Its advantage over amantadine is lower cost and a tablet 
formulation. Systemic review and meta-analysis in human studies suggests it has the potential to 
decrease pain, but adverse effects of dizziness are common (Kurian and others 2019). Potential 
adverse effects in dogs include ataxia, tremor and seizures
Amitriptyline 0.25–2 mg/kg PO SID/BID Tricyclic antidepressant blocking re-uptake of serotonin and norepinephrine neurotransmitters. 
The most common adverse effect is sedation, which is more likely with polypharmacy. Other 
possible adverse effects include hyperexcitability, seizures, dysrhythmias, bone marrow 
suppression, diarrhoea, vomiting, hypersalivation. Not advised in animals with seizures or 
epilepsy. Caution in patients with thyroid disorders, urinary retention, hepatic disorders, 
keratoconjunctivitis sicca, glaucoma, cardiac rhythm disorders or diabetes
(Possible) CSF-reducing drugs
Omeprazole 0.5–1.5 mg/kg PO SID/BID Inhibitor of H+/K+-activated ATPase (in the choroid plexus Na+/K+-ATPase regulates the production 
of CSF). In laboratory rodents long-term therapy reported to result in changes to the stomach lining. 
However, this effect has not been reported in dogs. Reported adverse effects include nausea, 
diarrhoea constipation and skin rashes
Cimetidine 5–7 mg/kg PO TID Histamine H2 receptor antagonists (epithelial cells of the choroid plexus possess histamine H2 
receptors). Adverse effects with this antacid are rare even at high doses. Liver and kidney toxicity 
have been reported. In people, cimetidine has been reported (rarely) to be associated with 
headache. Cimetidine may increase the kidney clearance of gabapentin
BID Twice a day, CSF Cerebrospinal fluid, PO Per os (orally) PRN Pro re nata, SID Once a day, TID Three times a day
*Dose I use. Unless otherwise indicated, start at the low end of the dose range and make increases based on effect and absence of adverse effects. Effect is assessed over a two to four-week period, except 
for amantadine, memantine and amitriptyline which require at least four weeks of use to assess effectiveness. Assessment of haematology and biochemistry is recommended before starting and at least 
annually for animals receiving long-term medication. Gabapentin and pregabalin are Schedule 3 controlled drugs under the Misuse of Drugs Regulations 2001 and Class C of the Misuse of Drugs Act 1971
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Craniocervical decompression surgery
Craniocervical decompression surgery (foramen 
magnum decompression) aims to decompress the 
craniospinal junction by removing the supraoccipital 
bone with a C1 rostral dorsal laminectomy. Tissue is 
removed until the cerebellum vermis is well exposed. 
In my experience, successful decompression also 
requires removal of the tough atlanto-occipital 
ligament and a durotomy. Closure varies between 
surgeons; I favour marsupialisation of the dura and 
covering the defect with biocompatible collagen 
matrix (Rusbridge 2007). Others advocate covering 
the bony defect with an implant typically of 
titanium mesh. Surgery is successful in reducing 
pain in approximately 80 per cent of cases; 
approximately 45 per cent of cases may still have a 
satisfactory quality of life two years after surgery, 
although many still receive long-term medication 
(Rusbridge 2007). Contrary to the analogous human 
condition, craniocervical decompression does not 
appear to address the factors leading to SM; the 
syrinx is generally persistent. Much of the clinical 
improvement is likely attributable to decompression 
of CSF pathways; that is, surgery is most useful for 
CM-P rather than SM-S. For some cases, recurrence 
of signs occurs, often attributed to fibrous tissue 
adhesions over the foramen magnum; 25 per cent 
to as many as 50 per cent of cases can eventually 
deteriorate (Rusbridge 2007). This can occur as 
early as two months following surgery. There is 
no convincing evidence that this is less likely with 
implanted surgery. Fibrous adhesions develop 
following blood contamination which is common 
with all surgery. 
Ventricular to peritoneal shunting
Ventricular to peritoneal shunting may be an option 
if the ventricles are significantly expanded, or if 
there is clinical hydrocephalus. This procedure 
appears to be more successful in facilitating syrinx 
collapse. However, shunting procedures have a high 
complication rate, especially subdural haematoma, 
infection and shunt blockage. 
Syringo to pleural or subarachnoid shunting
Syringo to pleural or subarachnoid shunting 
involves placement of a shunting device 
directly into the syrinx, allowing fluid to drain 
into the pleural cavity/subarachnoid space, 
respectively. Because of the risk of shunt blockage, 
Table 4 continued: Unlicensed drugs used in the medical management of CM-P and SM-S 
Drug Dose * Notes and adverse effects 
(Possible) CSF-reducing drugs continued
Acetazolamide 4–8 mg/kg SID Carbonic anhydrase inhibitor (enzyme involved in CSF secretion). Adverse effects are common 
especially with long-term use and may include anorexia, gastrointestinal signs, bone marrow 
depression, metabolic derangement (hypokalaemia, hypochloraemia, hyponatraemia, 
hyperglycaemia), hepatic insufficiency, hypersensitivity reactions (eg, rash) and CNS signs 
(sedation, depression, weakness, excitement). 
Corticosteroids
Prednisone/ 
Prednisolone/ 
methylprednisolone
0.5 mg/kg PO SID
then decrease to lowest 
possible, ideally alternate 
day, dose that controls 
signs
Neuroactive steroids modulate pain sensitivity and reduce neuropathic pain. Possible effect on 
aquaporin-4 expression (water channels) in spinal cord. An option for severe SM-S-associated 
weakness or phantom scratching. However, long-term use is not recommended due to adverse 
effects. Chronic use results in muscle loss, thereby increasing weakness and animals are 
often lethargic and heat intolerant; signs which are easily confused with CM-P and SM-S.
Other possible adverse effects include: vomiting; diarrhoea; increased urination and drinking 
and when combined with diuretics can result in potassium depletion; increased appetite 
and increased calorific intake that results in weight gain; skin changes and poor hair growth; 
delayed wound healing and increased susceptibility to infection. This drug should not be given 
to patients that are pregnant, have diabetes mellitus or kidney disease. 
Cannabinoids
Cannabidiol (CBD oil/
hemp extract) 
2 mg/kg BID# Cannabinoids act via cannabinoid receptors and affect the activities of many other receptors, 
ion channels and enzymes. They inhibit release of neurotransmitters and neuropeptides from 
presynaptic nerve endings, modulate postsynaptic neuron excitability, activate descending 
inhibitory pain pathways and reduce neural inflammation. Cannabinoids appear to be well 
tolerated in dogs. Serum biochemistry may show an increase in alkaline phosphatase, 
presumed due to liver enzyme induction. 
BID Twice a day, CM-P Chiari malformation-like associated pain, CNS Central nervous system, CSF Cerebrospinal fluid, PO Per os (orally), SID Once a day SM-S Syringomyelia-specific signs
*Dose I use. Unless otherwise indicated, start at the low end of the dose range and make increases based on effect and absence of adverse effects. Effect is assessed over a two to four-week period, except 
for amantadine, memantine and amitriptyline which require at least four weeks of use to assess effectiveness. Assessment of haematology and biochemistry is recommended before starting and at least 
annually for animals receiving long-term medication. Gabapentin and pregabalin are Schedule 3 controlled drugs under the Misuse of Drugs Regulations 2001 and Class C of the Misuse of Drugs Act 1971
#Dose based on the only published canine study (Gamble and others 2018) assessing CBD oil for pain associated with osteoarthritis; however, most commercial preparations do not contain enough 
compound to be able to achieve this dose. The UK Veterinary Medicines Directorate considers that veterinary products containing cannabidiol are veterinary medicines and therefore can only be 
administered with a veterinary prescription
Rusbridge.indd   264 02/06/2020   14:41
 o
n
 June 26, 2020 at BVA. Protected by copyright.
http://inpractice.bmj.com/
In Practice: first published as 10.1136/inp.m
1869 on 5 June 2020. Downloaded from
 
IN PRACTICE | June 2020 265
Companion animals
Fig 5: Treatment algorithm for Chiari-like malformation-
associated pain (CM-P) and syringomyelia-specific signs  
(SM-S). Refer to Table 4 for details. CSF Cerebrospinal fluid
CM-P
NSAIDs
SM-associated  
phantom scratching
Continuing pain
SM-associated gait 
abnormalities  
(weakness and  
postural deficits)
Gabapentin
Physiotherapy/
hydrotherapy
Continuing phantom 
scratching Consider referral/
surgical management
Add/switch  
to gabapentin Pregabalin (switch 
from gabapentin)
Continuing pain
Pregabalin (switch 
from gabapentin)
Continuing pain
Continuing phantom 
scratching
Referral for more medical options  
and/or surgical management
(Possible) CSF-reducing drugs
• Cimetidine
• Omeprazole
• Acetazolamide
Continuing gait  
abnormalities
Corticosteroids
(considered last resort)
Alter polypharmacy/ 
add additional drug
(aim for as few drugs  
as possible)
(Possible) CSF-reducing drugs
• Cimetidine
• Omeprazole
• Acetazolamide
Topiramate
Amitriptyline
Amantadine or 
memantidine
Paracetamol
For ‘top up’ medication  
during breakthrough pain
Cannabinoids 
(CBD oil)
Complementary therapy
(eg, acupuncture)
subarachnoid adhesions and complications 
relating to the myelotomy, I only use this technique 
when other surgeries are inappropriate; for 
example, in the instance of SM secondary to 
arachnoid webs (Tauro and Rusbridge 2020). 
Which dogs are surgical candidates? 
Surgery is more clearly indicated and most likely to 
be considered successful in dogs with CM-P (with or 
without SM) that have responded incompletely or 
not at all to medical management. In this instance, 
a craniocervical decompression is probably the 
surgery of choice. However, if clinical signs reflect 
SM (eg, phantom scratching or weakness) then this 
procedure is less likely to be successful because the 
syrinx persists. Many cases with phantom scratching 
can be managed medically. Management of weakness 
is more challenging, especially as there are no 
surgical reports that provide MRI evidence of long-
term postoperative syrinx collapse. 
Complementary therapy 
Failure to control clinical signs and perceived or 
actual drug adverse effects drive many owners to 
seek alternative therapy. Anecdotally, acupuncture 
has been reported to be a useful adjunctive therapy 
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for some cases. In others, massage may help 
alleviate signs. Care should be taken as the response 
to these treatments varies with each animal and 
some dogs may be more painful afterwards. Spinal 
manipulation is not recommended because it may 
cause pain. Exercise should be encouraged, and 
excessive weight gain discouraged. Hydrotherapy 
can be useful for some patients, especially those 
with weakness or proprioceptive deficits. 
Genetic factors and breeding advice 
The high prevalence, within closely related 
populations, suggests that SM is inherited in dogs and 
studies have shown it to be a complex trait, which can 
be late onset with a moderately high heritability that 
likely involves genes involved in embryonically active 
pro-osteogenic signalling pathways. Since the early 
2000s, it has been recommended that dogs of breeds 
predisposed to CM and SM be MRI screened at least 
twice in their lifetime. 
Breeding recommendations based on SM status 
and ages were formulated in 2006 (Knowler and 
others 2011). These guidelines concentrated on 
removing dogs with early onset SM from the breeding 
pool while maintaining genetic diversity. Early 
results from this breeding programme indicated that 
offspring without SM were more common when the 
parents were both clear of SM. Conversely, offspring 
with SM were more likely when both parents had SM. 
In the UK, MRI screens of potential breeding stock 
can be undertaken through the BVA/Kennel Club’s 
canine health scheme. However, this does not assess 
the whole skull or cranial cervical vertebrae nor does 
it provide an objective measure of risk of developing 
CM-P or SM. A machine learning approach is being 
developed with the ultimate aim of creating a simple 
artificial intelligence tool which will provide an 
objective measure of risk of developing CM-P or SM in 
the future (Spiteri and others 2019). 
Summary 
CM and SM is an inherited disorder with a high 
morbidity in many brachycephalic toy breeds and 
crosses. It is a pathology affecting the entire skull 
and craniocervical junction and is characterised by: 
■■ shortened basicranium; 
■■ craniofacial hypoplasia; 
■■ increased cranial height; 
■■ rostral displacement of atlas and dens; 
■■ overcrowding of the craniocervical junction; 
■■ obstruction of CSF flow through the foramen 
magnum; 
■■ and development of fluid filled cavities in the 
central spinal cord. 
Although some dogs have no clinical signs, others 
can present with pain (CM-P) and signs relating to 
spinal cord damage by the syrinx (SM-S). Surgical 
and medical treatment options are available, but 
these have limited success, and from a welfare point 
of view it would be better to implement a screening 
and breeding programme that limits the occurrence 
of this disabling disease. 
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